Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-30, 17:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-26, 15:12
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-23, 00:13
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-16, 21:10
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-13, 19:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-09, 17:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-08, 03:05
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-04-17, 22:38
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-28, 19:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-24, 22:00
